Robeco Schweiz AG raised its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 47.4% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,398 shares of the company’s stock after buying an additional 771 shares during the quarter. Robeco Schweiz AG’s holdings in Eli Lilly and Company were worth $2,775,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Brucke Financial Inc. raised its stake in Eli Lilly and Company by 47.7% during the third quarter. Brucke Financial Inc. now owns 1,768 shares of the company’s stock worth $2,046,000 after purchasing an additional 571 shares during the period. Signaturefd LLC boosted its holdings in Eli Lilly and Company by 3.7% in the 3rd quarter. Signaturefd LLC now owns 27,035 shares of the company’s stock valued at $31,282,000 after purchasing an additional 961 shares during the last quarter. BG Investment Services LLC boosted its holdings in Eli Lilly and Company by 3,833.7% in the 3rd quarter. BG Investment Services LLC now owns 10,975 shares of the company’s stock valued at $12,699,000 after purchasing an additional 10,696 shares during the last quarter. Bond & Devick Financial Network Inc. grew its stake in shares of Eli Lilly and Company by 24.2% in the 3rd quarter. Bond & Devick Financial Network Inc. now owns 452 shares of the company’s stock valued at $523,000 after buying an additional 88 shares during the period. Finally, Evanson Financial LLC grew its stake in shares of Eli Lilly and Company by 15.0% in the 3rd quarter. Evanson Financial LLC now owns 790 shares of the company’s stock valued at $915,000 after buying an additional 103 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Eli Lilly and Company
In related news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares of the company’s stock, valued at $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is currently owned by corporate insiders.
Trending Headlines about Eli Lilly and Company
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: A federal judge rejected Novo Nordisk’s request to block Lilly’s advertisements for its obesity treatments, finding insufficient evidence that the campaign caused meaningful or lasting harm to Novo’s sales. The decision allows Lilly to continue promoting its weight-loss portfolio, including Zepbound. Reuters article
- Positive Sentiment: New early-stage oncology data added to Lilly’s pipeline narrative. Olomorasib reportedly produced a 62% response rate in lung-cancer data, while Phase 1 results for sofe-M plus bevacizumab showed encouraging response and disease-control rates in ovarian cancer without major new safety signals. These results remain preliminary but could support longer-term growth expectations. Lung cancer results
- Positive Sentiment: Bernstein raised its price target for LLY to $1,450 from $1,385, reflecting continued confidence in Mounjaro, Zepbound and Lilly’s broader growth prospects. Commentary also notes that Lilly has significantly outperformed broader equities over the past five years. Bernstein price-target update
- Positive Sentiment: LillyDirect is working with Counsel Health on an AI-enabled, physician-led weight-management program, potentially expanding access and patient engagement around Lilly’s GLP-1 medicines. Counsel Health partnership
- Neutral Sentiment: International business chief Patrik Jonsson will retire at year-end after 36 years, with Ilya Yuffa becoming president of Lilly Global Markets on January 1, 2027. The planned transition is intended to support global expansion, but it introduces a leadership change investors will monitor. Lilly leadership announcement
- Neutral Sentiment: Lilly declared a quarterly dividend of $1.73 per share, payable December 10 to shareholders of record November 13. The 0.5% yield is modest, making the announcement more of a continuity signal than a major valuation catalyst. Dividend announcement
- Negative Sentiment: Ahead of earnings, analysts continue to flag pricing pressure, rising costs and intense competition from Novo Nordisk. Investors will focus on Mounjaro and Zepbound demand, patient growth, revenue realization and updated guidance; strong expectations increase the risk of a muted reaction if results or outlook fall short. Q3 earnings preview
Eli Lilly and Company Trading Up 0.3%
Shares of NYSE LLY opened at $1,283.52 on Wednesday. Eli Lilly and Company has a 12-month low of $809.63 and a 12-month high of $1,321.21. The business’s fifty day simple moving average is $1,191.27 and its 200-day simple moving average is $1,088.34.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. During the same quarter last year, the business posted $6.31 earnings per share. The company’s revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts forecast that Eli Lilly and Company will post 33.22 earnings per share for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on the stock. TD Cowen restated a “buy” rating and set a $1,250.00 price target on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. Guggenheim lifted their price target on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a “buy” rating in a research report on Friday, September 18th. The Goldman Sachs Group reiterated a “buy” rating and issued a $1,413.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, October 20th. UBS Group set a $1,376.00 price objective on Eli Lilly and Company in a research report on Friday, August 7th. Finally, Truist Financial raised their target price on Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $1,320.25.
Read Our Latest Stock Analysis on LLY
Eli Lilly and Company Profile
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.
The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.
Read More
- Five stocks we like better than Eli Lilly and Company
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
